MorphoSys Announces Clinical Milestone
in Oncology Program
Prime Standard Segment,
TecDAX, OTC: MPSYY) announced today that it has received a milestone payment
from Novartis in connection with the initiation of a phase 1 clinical trial of
a HuCAL antibody in the field of oncology. This becomes the tenth therapeutic
antibody made using MorphoSys's technologies that Novartis is evaluating in
clinical trials. The associated milestone payment is booked in 2014.
"In 2014 our
pipeline, and our collaborators' pipelines of therapeutic antibodies have
matured significantly and now include more programs in clinical trials and in a
more advanced state than ever before. Today's news represents the fourth
clinical milestone with our partners during the course of the year,"
commented Dr. Marlies Sproll, Chief Scientific Officer of MorphoSys AG.
MorphoSys's collaboration
with Novartis has resulted in ten clinical programs to date, five of which are
in phase 1 development, with another four programs in phase 2 and one in phase
3. In total, MorphoSys's partnered and proprietary clinical pipeline currently
comprises 22 unique antibody molecules which are being evaluated in more than
60 clinical trials.
No comments:
Post a Comment